Claude hit 93 percent on de novo protein binders across 15

Anthropic's Claude AI model achieved a 93% success rate in designing functional de novo protein binders for 14 of 15 targets, with wet-lab validation by Adaptyv Bio and Twist Bioscience, according to a report. The result, if confirmed, represents a significant improvement over typical single-digit to low-teens success rates of existing de novo pipelines like RFdiffusion and Chroma, though missing details on affinity thresholds and target classes limit direct comparisons.

Claude hit 93 percent on de novo protein binders across 15 Claude /en/tags/claude/ designed functional binders for 14 of 15 targets — validated by Adaptyv Bio and Twist Bioscience, not internal benchmarks — is the kind of result that forces a rethink of where LLM-driven protein engineering actually sits right now. Most published de novo pipelines using RFdiffusion or Chroma report single-digit to low-teens success rates per design round. A 93 percent hit rate, if the denominator and affinity thresholds hold up, isn't incremental. It's a category shift. What the benchmark actually tells us The human expert wrote the prompt. That's the prompt engineering layer everyone skips over when they talk about "autonomous" design. Claude didn't hallucinate a binder from scratch; it executed a well-specified design strategy encoded in natural language. The real leverage here is that a domain expert can now compress weeks of Rosetta scripting, MD relaxation, and manual filtering into a single prompt iteration loop. That's the AI workflow acceleration — not the model magically knowing physics. Adaptyv and Twist doing the wet-lab validation is the critical piece. Self-reported metrics in this space have been unreliable for years. Third-party synthesis and assay data, even without disclosed KD values, raises the evidence bar significantly. Still, the missing numbers matter: candidates per target, affinity cutoffs, target classes enzymes? PPIs? allosteric sites? , and whether any designs failed expression or solubility screens. Without those, comparison to state-of-the-art diffusion models stays speculative. Where the bottleneck moves next If this reproduces, the constraint shifts from design to functional validation . High-throughput synthesis and binding assays are already scalable. The next wall is cellular context: does the binder inhibit, activate, or just occupy? Does it fold in vivo? Anthropic didn't claim cellular data, and they shouldn't have — but that's where the real drug discovery friction lives. What I'm watching - A technical report with target identities, candidate counts per target, and affinity distributions - Independent labs replicating the prompt strategy on held-out target sets - Whether the same prompt template generalizes across target classes or overfits the test set The prompt itself — if Anthropic releases it — becomes a more valuable artifact than any single binder sequence. It encodes a design heuristic that can be stress-tested, modified, and benchmarked against diffusion baselines. That's the real open science contribution here. Next Reasoning prefills might be a sign of benchmark distillation → /en/threads/6811/